SCHEMBL612923

SCHEMBL612923

O=Cc1ccccc1-c1ccoc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.49
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 1/20 0.44
THRB P10828 1/20 0.44
BLM P54132 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
IMPDH2 P12268 2/20 0.42
XDH P47989 1/20 0.41
ALDH1A1 P00352 2/20 0.38
TSHR P16473 1/20 0.38
TRIM24 O15164 1/20 0.38
TRIM33 Q9UPN9 1/20 0.38
NAT1 P18440 2/20 0.37
GPR84 Q9NQS5 1/20 0.37
PELI1 Q96FA3 1/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31074157 1.00 ERN1 (0.49) ERN1MEN1KMT2ALMNATHRB
SCHEMBL96128 0.84 ERN1 (0.51) ERN1MEN1KMT2ALMNATHRB
SCHEMBL21437969 0.82 ERN1 (0.51) ERN1IMPDH2TRIM24TRIM33GPR84
SCHEMBL15646561 0.78 ERN1 (0.48) ERN1PELI1
SCHEMBL15645545 0.78 ERN1 (0.63) ERN1MEN1KMT2ALMNAALDH1A1
SCHEMBL13746042 0.77 CDK8 (0.69) IMPDH2CLK4
SCHEMBL30497064 0.77 LMNA (0.60) ERN1MEN1KMT2ALMNATHRB
SCHEMBL11768743 0.77 LMNA (0.60) ERN1MEN1KMT2ALMNATHRB
SCHEMBL29030856 0.76 PTGER3 (0.55) MEN1KMT2AALDH1A1NAT1PELI1
SCHEMBL28853937 0.76 MEN1 (0.37) ERN1MEN1KMT2ALMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4582903-A Synthesis of unsaturated hydantoins with an inexpensive catalyst STAUFFER CHEMICAL COMPANY (US) 1986-04-15 US claimed
US-4345072-A Process for the production of 5-arylidene hydantoins (B) DEGUSSA AG (DE) 1982-08-17 US claimed
EP-3808740-A1 ORAL DOSAGE FORMS COMPRISING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TerSera Therapeutics LLC (US) 2021-04-21 EP disclosed
EP-3176159-B1 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS INC (US) 2020-10-21 EP disclosed
US-10654878-B2 Compounds of phosphinanes and azaphosphinanes, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2020-05-19 US disclosed
US-10336743-B2 Aminopyrimidine kinase inhibitors Jasco Pharmaceuticals, LLC (US) 2019-07-02 US disclosed
US-20190031693-A1 COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2019-01-31 US disclosed
US-20180016288-A1 COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2018-01-18 US disclosed
US-20180016288-A1 COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2018-01-18 US disclosed
EP-2091940-B3 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS INC (US) 2017-12-06 EP disclosed
WO-2017121969-A1 NOVEL PHOSPHINANE AND AZAPHOSPHINANE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2017-07-20 WO disclosed
US-6080773-A USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS AKZO NOBEL, N.V. (NL) 2000-06-27 US disclosed
WO-1999018941-A2 Ih-MODULATORS AKZO NOBEL N.V. (NL) 1999-04-22 WO disclosed
US-4684735-A Promotion of raney nickel hydrogenation catalyst STAUFFER CHEMICAL COMPANY (US) 1987-08-04 US disclosed
US-4650876-A INCREMENTAL ADDITION TO PREVENT FOAMING, RANEY CATALYST STAUFFER CHEMICAL COMPANY (US) 1987-03-17 US disclosed
EP-0210683-A1 Promotion of raney nickel catalyst STAUFFER CHEMICAL COMPANY (US) 1987-02-04 EP disclosed
US-4613691-A Preparation of amino acids from unsaturated hydantoins STAUFFER CHEMICAL COMPANY (US) 1986-09-23 US disclosed
US-4582903-A Synthesis of unsaturated hydantoins with an inexpensive catalyst STAUFFER CHEMICAL COMPANY (US) 1986-04-15 US disclosed
EP-0177072-A2 Preparation of amino acids from unsaturated hydantoins STAUFFER CHEMICAL COMPANY (US) 1986-04-09 EP disclosed
US-4345072-A Process for the production of 5-arylidene hydantoins (B) DEGUSSA AG (DE) 1982-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10654878-B2 Compounds of phosphinanes and azaphosphinanes, a process for their preparation and pharmaceutical compositions containing them TK1, AK1, PHKA1 ERN1 411/4885MEN1 3652/4885KMT2A 1104/4885
US-20180016288-A1 COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TK1, AK1, PHKA1 ERN1 411/4885MEN1 3652/4885KMT2A 1104/4885
US-10336743-B2 Aminopyrimidine kinase inhibitors PIM1, PIM2, PIM3 ERN1 572/4885MEN1 4251/4885KMT2A 1155/4885
US-20190031693-A1 COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AK1, TK1, PHKA1 ERN1 402/4885MEN1 3796/4885KMT2A 1559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.